Business
After years of contraction, investors see biotech reentering a growth cycle driven by scientific progress, asset quality and renewed conviction in oncology, obesity and neuroscience innovation.
FEATURED STORIES
With the biopharma industry performing better of late, analysts, executives and other industry watchers are “cautiously optimistic”—a term heard all over the streets of San Francisco at the J.P. Morgan Healthcare Conference earlier this month.
Attendance at the Biotech CEO Sisterhood’s annual photo of women leaders and allies in Union Square doubled this year. There’s still more work to do.
After winning a surprise approval for its hereditary angioedema drug Ekterly, KalVista is confident the oral offering will capture the lion’s share of the market for on-demand use.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
In people with diabetes, periods of high blood sugar (hyperglycemia) can negatively impact their health years later, even if they get their blood sugar under control.
Like almost all conferences this year, Citi’s 15th Annual BioPharma Conference 2020 is being held virtually.
Rockville, Maryland-based OncoImmune closed on a Series B round worth $56 million.
For patients with epilepsy, the diagnosis and treatment process can be long, arduous, and filled with lengthy hospital stays. The medical device company NeuroOne Medical Technologies Corporation hopes to change that.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 9, 2020.
Using gene therapy to edit embryos, sperm or eggs in order to improve health conditions in a child should not be conducted due to the unreliability of the science, as well as due to significant ethical and moral concerns.Those are the words found in new guidance established this week.
It was a busy week for both COVID-19-related clinical trial news and the rest of the industry. Here’s a look.
AbbVie and I-Mab announced today that they had entered a global collaboration agreement to develop and commercialize lemzoparlimab (also known as TJC4). The anti-CD47 monoclonal antibody was initially discovered and developed by I-Mab for the treatment of various cancers.
Biopharma and life science companies from across the globe strengthen their leadership teams and boards with these Movers & Shakers.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 4, 2020.